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Abstract 
Nephrotic-range proteinuria, which denotes structural damage to the glomerular 
filtration barrier, occurs in 1–2% of bevacizumab-treated patients. The glomerular injury 
and subsequent proteinuria is probably due to a direct targeting of vascular endothelial 
growth factor (VEGF). We report a case series of six patients who developed a syndrome 
characterized by proteinuria and hypertension after starting therapy with bevacizumab 
and who experienced prolonged progression-free survival. Given that altered glomerular 
permeability appears to be a direct consequence of VEGF inhibition, we hypothesize that 
proteinuria may indeed correlate with drug efficacy. Optimizing safe and effective drug 
dosing is critical to achieve the best therapeutic impact due to limited treatment options 
for many life-threatening advanced cancers. Clinicians should be aware that the 
development of proteinuria might serve as a surrogate marker of bevacizumab antitumor 
efficacy and determine the appropriate criteria for withholding this effective anticancer 
therapy. 
 
Introduction 
The humanized monoclonal antibody bevacizumab (Avastin Genentech/Roche) is 
increasingly used to treat malignant solid tumors. This antibody recognizes and blocks 
vascular endothelial growth factor (VEGF)-A [1]. The latter is a chemical signal that 
stimulates the growth of new blood vessels (angiogenesis). In the kidney, glomerular 
podocytes express VEGF and glomerular endothelial cells express VEGF receptors.  
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Podocyte-specific deletion of a single VEGF allele causes proteinuria and capillary 
endotheliosis in rodents, and disrupted glomerular VEGF signaling is strongly implicated 
in the pathogenesis of human preeclampsia, a syndrome characterized by proteinuria and 
hypertension [2–4]. 
Case Presentation 
In the institutional review case series described here, six patients developed a syndrome 
characterized by proteinuria and hypertension after starting therapy with bevacizumab. History of 
patients before commencing treatment, was unremarkable for hypertension and kidney disease, while 
urinalysis was normal. Patients were identified clinically after developing edema, hypertension, 
proteinuria, and/or hypoalbuminemia (table 1). All six patients developed proteinuria grade 2 (2–3+ 
protein in dipstick urinalysis or 1.0–3.5 g in 24-hour urine for protein) or higher, and new or 
exacerbated hypertension required on average two antihypertensive medications. Glomerulonephritis 
and microangiopathic hemolytic anemia were excluded based on the results of blood and urine 
sediment tests. In most patients, the bevacizumab dose was either reduced or discontinued. 
Subsequently, in patients with follow-up information, there was a dramatic improvement (patients 1, 2, 
3, 5) of proteinuria. 
Since 2003, at least 481 patients have been treated with bevacizumab at our institution; thus, the 
cumulative crude incidence of renal adverse events is 1.2%. However, the true prevalence of 
bevacizumab-associated renal toxicity is likely higher because patients were not routinely screened in a 
systematic, prospective, and long-term manner for the development of new proteinuria. 
Interestingly, all patients experienced prolonged progression-free survival, defined as the time 
interval from treatment initiation to documented progression or death. With the exception of one of the 
patients, who received paclitaxel and bevacizumab as first-line treatment for metastatic breast cancer, all 
other patients received the antibody in combination with various agents as fourth- or fifth-line 
treatment. Progression-free survival of more than 16 months for taxane/anthracycline refractory 
metastatic breast cancer, or of more than 6 months for a heavily pre-treated patient with metastatic 
non-small cell lung cancer, compared favorably to reported trials of such patient populations [5, 6]. 
Even the patient with small cell lung cancer died as a result of septic shock secondary to infection, 
without evidence of disease progression. 
Discussion 
Nephrotic-range proteinuria, which denotes structural damage to the glomerular 
filtration barrier, occurs in 1–2% of bevacizumab-treated patients [7]. Although several 
potential causes of this type of proteinuria have been suggested [8, 9], it is difficult to 
distinguish the general effects of therapy, such as an immunologic response to the 
monoclonal antibody, from the direct effects due to inhibition of endogenous VEGF 
signaling in non-cancerous tissues. Recently, it was shown that local reduction of VEGF 
within the kidney was sufficient to trigger the pathogenesis of thrombotic 
microangiopathy by the use of a conditional gene targeting to delete VEGF from renal 
podocytes in adult mice. This resulted in a profound thrombotic glomerular injury, 
providing evidence that the glomerular injury of patients treated with bevacizumab is 
probably due to a direct targeting of VEGF by the antiangiogenic therapy [10]. 
Given that the altered glomerular permeability appears to be a direct consequence of 
VEGF inhibition, proteinuria may indeed correlate with drug efficacy [10]. Interestingly, 
hypertension, which represents another vascular toxicity of bevacizumab, has already 
been proposed as a predictive marker for antiangiogenic treatment efficacy [11].  
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Whether the development of proteinuria might also serve as a surrogate marker of 
antitumor efficacy is unknown. This could be proven only in the context of a clinical trial 
designed specifically to address this question. However, a large number of patients should 
be enrolled in such a study due to the relative low incidence of grade 2 or higher 
proteinuria [7]. In addition, the recent FDA Oncologic Drugs Advisory Committee’s vote 
in favor of removing the metastatic breast cancer indication from the drug labeling makes 
the design of such a trial highly unlikely. 
On the other hand, treatment options for these life-threatening advanced cancers are 
limited, and optimizing safe and effective drug dosing may be critical to achieve the best 
therapeutic impact. Clinicians should be aware of the hypothesis that individuals 
experiencing bevacizumab-induced proteinuria potentially represent a group of patients 
who derive a great benefit from anti-angiogenic treatment and consider the pros and cons 
before withholding this effective anticancer therapy. 
 
 
 
Table 1. Summary of patients who experienced prolonged disease-free survival and bevacizumab-
induced proteinuria 
No. Age/ 
gender 
Cancer Line 
of treat- 
ment 
Regimen 
(+bevacizumab) 
Worsening/ 
new onset 
HTN 
Grade 
of pro- 
teinuria 
Res- 
ponse 
PFS 
(mo) 
1 60/F  Breast 4  Letrozole  yes  2  SD  16+ 
2 76/M NSCLC  5  Pemetrexed  yes  2  SD  06+ 
3 75/F  Breast 1  Paclitaxel  yes  2  CR  09+ 
4 49/F  Breast 5  Lapatinib  yes  2  SD  06 
5 65/F  Breast 4  Vinorelbine  yes  2  SD  13+ 
6 70/M SCLC  4  Paclitaxel  yes  4  SD  03 
HTN = Hypertension; PFS = progression-free survival; NSCLC = non-small cell lung 
cancer; SCLC = small cell lung cancer; SD = stable disease; CR = complete remission; mo = 
months. 
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